- mAbxience and Egis form a strategic agreement to commercialize biosimilars in Central and Eastern Europe, enhancing Fresenius Kabi’s biopharma reach and commitment to affordable healthcare.
Tue Nov 12 09:17:35 -2024 UTC– mAbxience and Egis signed a strategic commercialization agreement for biosimilar candidates in Central and Eastern Europe.
This partnership strengthens Fresenius Kabi’s presence in the region, emphasizing their commitment to enhancing access to high-quality biosimilar therapies.